- Department for International Development
- Document Type:
- Journal Article
- Smith, R., Pinoges, L., Kiechel, J.R., Jullien, V., Carn, G. Jones, J.J., Ashley, E.A., Baudin, E., Comte, E., Guérin, P.J., Mazinda, C.S., Schramm, B., Sundaygar, T., Valeh, P., Zolia, Y.M., Boum, Y., Dhorda, M., and Houze, P.
Background: Prospective efficacy monitoring of anti-malarial treatments is imperative for timely detection of resistance development. The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC) was compared to that of artemether-lumefantrine (AL) among children aged six to 59 months in Nimba County, Liberia, where Plasmodium falciparum malaria is endemic and efficacy data are scarce. Methods: An open-label, randomized controlled non-inferiority trial compared the genotyping adjusted day 42 cure rates of ASAQ FDC (ASAQ Winthrop®) to AL (Coartem®) in 300 children aged six to 59 months with uncomplicated falciparum malaria. Inclusion was between December 2008 and May 2009. Randomization (1:1) was to a three-day observed oral regimen (ASAQ: once a day; AL: twice a day, given with fatty food). Day 7 desethylamodiaquine and lumefantrine blood-concentrations were also measured. Results: The day 42 genotyping-adjusted cure rate estimates were 97.3% [95% CI: 91.6-99.1] for ASAQ and 94.2% [88.1-97.2] for AL (Kaplan-Meier survival estimates). The difference in day 42 cure rates was −3.1% [upper limit 95% CI: 1.2%]. These results were confirmed by observed proportion of patients cured at day 42 on the per-protocol population. Parasite clearance was 100% (ASAQ) and 99.3% (AL) on day 3. The probability to remain free of re-infection was 0.55 [95% CI: 0.46-0.63] (ASAQ) and 0.66 [0.57-0.73] (AL) (p = 0.017). Conclusions: Both ASAQ and AL were highly efficacious and ASAQ was non-inferior to AL. The proportion of patients with re-infection was high in both arms in this highly endemic setting. In 2010, ASAQ FDC was adopted as the first-line national treatment in Liberia. Continuous efficacy monitoring is recommended.
Schramm, B.; Valeh, P.; Baudin, E.; Mazinda, C.S.; Smith, R.; Pinoges, L.; Dhorda, M.; Boum, Y.; Sundaygar, T.; Zolia, Y.M.; Jones, J. J.; Comte, E.; Houze, P.; Jullien, V.; Carn, G.; Kiechel, J.R.; Ashley, E.A.; Guérin, P.J. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malaria Journal (2013) 12 (1) 251. [DOI: 10.1186/1475-2875-12-251]
Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial
Document Type: Journal Article
Authors: Smith, R. Pinoges, L. Kiechel, J.R. Jullien, V. Carn, G. Jones, J.J. Ashley, E.A. Baudin, E. Comte, E. Guérin, P.J. Mazinda, C.S. Schramm, B. Sundaygar, T. Valeh, P. Zolia, Y.M. Boum, Y. Dhorda, M. Houze, P.